Evonik Venture Capital

Evonik Venture Capital, the corporate venture arm of Evonik Industries, manages a fund size of €400 million and has made over 50 investments since 2012. The firm strategically invests in innovative startups across various growth fields such as Nutrition & Care, Smart Materials, Specialty Additives, and Digitalization, with a strong focus on sustainability and carbon neutrality technologies​. Evonik's portfolio includes startups like Interface Polymers, which develops additives for easier recycling of plastics, and SuperC, a leader in graphene materials for improving lithium-ion batteries. Other notable investments are Allay Therapeutics, which has developed a post-surgery pain relief implant, and Citrine Informatics, an AI-driven platform for materials and chemicals development​. The venture capital unit emphasizes early to growth-stage investments, with typical investment volumes of up to €15 million per portfolio company. They aim to be an active partner, providing strategic, technical, and commercial support, and leveraging their extensive network for the growth of their portfolio companies. Evonik Venture Capital operates globally with offices in Germany, the USA, and China, making them well-positioned to support innovative startups in key regions worldwide.